Department of Cardiology, Shanghai Chest Hospital, Shanghai Jiao Tong University, 241 West Huaihai Road, Shanghai, 200030, China.
University of Illinois, 808 South Wood Street, Chicago, Illinois, 60612.
Catheter Cardiovasc Interv. 2019 Aug 1;94(2):E88-E95. doi: 10.1002/ccd.27371. Epub 2017 Dec 7.
This study aimed to compare the efficacy and safety of two different treatments of paravalvular leak (PVL).
PVL is a common complication after surgical valve replacement. Re-operation is associated with high mortality, morbidity, and risk of re-leak. Catheter-based repair has emerged as a promising new therapy.
Eighty-seven consecutive patients with symptomatic PVL received either transcatheter (n = 46) or surgical (n = 41) treatment at Shanghai Chest Hospital between January 2009 and December 2015.The procedural and clinical success rates were similar between the transcatheter group and the surgical group (82.6 vs. 90.2%; P = 0.30; and 69.5 vs. 73.0%; P = 0.71, respectively). There were fewer in-hospital total major adverse events in the transcatheter group (56.09 vs. 17.39%; P < 0.001), and transcatheter repair was more cost-effective, with fewer blood transfusions, shorter procedure durations, shorter hospital stays, and less expenditure. However, there were six cases of hemolysis aggravation in the transcatheter group (13.04%). The 5-year overall survival rates after transcatheter and surgical repair were 74.39 and 71.95% (P = 0.45), respectively, and the cardiac-related survival rates were 84.08 and 74.72% (P = 0.19), respectively.
Transcatheter and surgical repairs are both effective treatments for selected patients with PVL. And, transcatheter closure seems to be safer and more cost-effective. Nonetheless, this new treatment may be risky for post-procedure hemolysis when unsuitable devices are used.
本研究旨在比较两种不同的瓣周漏(PVL)治疗方法的疗效和安全性。
PVL 是心脏瓣膜置换术后的常见并发症。再次手术与高死亡率、发病率和再漏风险相关。经导管修复已成为一种有前途的新疗法。
2009 年 1 月至 2015 年 12 月,上海胸科医院连续收治 87 例有症状的 PVL 患者,分别接受经导管(n=46)或手术(n=41)治疗。经导管组和手术组的程序和临床成功率相似(82.6%比 90.2%;P=0.30;69.5%比 73.0%;P=0.71)。经导管组住院期间总不良事件发生率较低(56.09%比 17.39%;P<0.001),经导管修复更具成本效益,输血量较少,手术时间较短,住院时间较短,支出较少。然而,经导管组有 6 例溶血加重(13.04%)。经导管和手术修复后的 5 年总生存率分别为 74.39%和 71.95%(P=0.45),心脏相关生存率分别为 84.08%和 74.72%(P=0.19)。
经导管和手术修复都是治疗 PVL 患者的有效方法。经导管封堵似乎更安全、更具成本效益。然而,当使用不合适的器械时,这种新的治疗方法可能会增加术后溶血的风险。